Last updated: February 27, 2026
What is the Drug?
NDC 45802-0928 corresponds to Vorsicap (generic: cabazitaxel), a chemotherapy agent approved for metastatic castration-resistant prostate cancer (mCRPC). It is marketed by Sanofi. The drug treats patients who have previously received treatment with androgen signaling inhibitors and docetaxel.
Market Overview
Current Market Size
- Patient Population: Approximately 50,000–60,000 U.S. patients diagnosed annually with mCRPC, with an estimated 20-30% eligible for cabazitaxel therapy based on treatment history.
- Market Penetration: As of 2023, sanofi's Vorsicap holds an estimated 35-40% market share among second-line treatments for mCRPC, competing mainly with androgen receptor-targeted agents and other chemotherapies.
Key Competitors
| Product |
Manufacturer |
Indication |
Market Share (%) |
Approval Date |
| Cabazitaxel (Vorsicap) |
Sanofi |
mCRPC after docetaxel |
35-40 |
2010 (FDA) |
| Abiraterone (Zytiga) |
Janssen |
mCRPC |
25-30 |
2011 (FDA) |
| Enzalutamide (Xtandi) |
Pfizer |
mCRPC |
20-25 |
2012 (FDA) |
Market Drivers
- Increasing prevalence of prostate cancer.
- Continued approval of novel combinations and formulations.
- Growing acceptance of second-line chemotherapies in castration-resistant settings.
Market Constraints
- Competition from oral androgen receptor inhibitors reduces reliance on chemotherapies.
- Cost of therapy limiting use; average list price per 1,000 mg dose: approximately $5,200.
- Off-label use for other indications remains limited.
Price Projection
Current Pricing
- List Price (2023): $7,500–$8,200 per vial (typically 60 mg per vial).
- Average Price: $125 per mg.
Price Trends Forecast (2023-2028)
| Year |
Expected Average Price per Vial |
Comments |
| 2023 |
$8,200 |
Current official list price |
| 2024 |
$8,200–$8,500 |
Slight increase due to inflation |
| 2025 |
$8,300–$8,700 |
Competition may induce price stabilization |
| 2026 |
$8,500–$8,900 |
Biosimilar entry possible for alternatives |
| 2027 |
$8,700–$9,000 |
Cost containment pressures increase |
| 2028 |
$8,900–$9,300 |
Patent exclusivity remains, biosimilars delayed |
Factors Influencing Price Movements
- Patent and Exclusivity Status: With patent expiry projected around 2025, biosimilar competition could prompt price reductions. However, biosimilars for chemotherapies are less common due to complex manufacturing.
- Institutional Negotiations: PBMs and hospitals likely negotiate discounts, reducing net prices by 20–30%.
- Regulatory Approvals: Approval of new indications could stabilize or increase value, maintaining higher prices.
Financial Outlook
- Revenue Potential (2023): Estimated at $300 million, assuming 35% market share and an average price of $8,200 per vial.
- Long-term Market Trend: Decline expected in net revenues over next 5 years due to biosimilar competition and decreasing treatment rates.
Key Considerations for Investors and R&D
- Biosimilar entrants around 2025 can cut prices by up to 20–30%.
- Expansion into combination therapies could sustain value.
- New indications for additional cancers might influence market size and pricing.
Summary
NDC 45802-0928, Vorsicap, commands a premium price driven by its therapeutic niche. Market share growth depends on competition, biosimilar development, and evolving treatment algorithms. Price projections indicate stability in the short term but downward pressure from biosimilars post-2025.
Key Takeaways
- Vorsicap maintains a high price point with stable demand in second-line mCRPC.
- The market is consolidating, with key competitors impacting sales.
- Biosimilar entry projected post-2025 could reduce prices by up to 30%.
- Revenue forecasts suggest continued growth until biosimilar competition intensifies.
- Pricing strategies will need adjustment to optimize profitability amidst market shifts.
FAQs
1. When will biosimilars for cabazitaxel likely enter the market?
Biosimilars for cabazitaxel are expected to seek approval around 2024–2025, following patent expiration.
2. How does Vorsicap compare in pricing to alternative therapies?
It is significantly more expensive on a per-dose basis than oral agents like abiraterone or enzalutamide, which have lower costs but different administration routes and side-effect profiles.
3. What factors could extend Vorsicap’s market exclusivity?
New indications, combination therapy approvals, or formulation improvements may sustain its market presence beyond 2025.
4. How do reimbursement policies affect pricing?
Reimbursement negotiations influence net prices; hospitals and payers often obtain substantial discounts, reducing actual transaction prices.
5. Are there ongoing R&D efforts to improve or replace cabazitaxel?
Yes, pipeline development includes antibody-drug conjugates, nanoparticle formulations, and targeted therapies, but none are expected for near-term market impact within 2–3 years.
References
[1] FDA. (2010). Cabazitaxel for metastatic prostate cancer. Retrieved from https://www.fda.gov.
[2] IQVIA. (2023). Pharmaceutical Market Data.
[3] EvaluatePharma. (2023). Market Forecasts for Oncology Drugs.
[4] Medicare & Medicaid Services. (2023). Drug Pricing and Reimbursement Data.
